Cogentix Medical (CGNT) vs. Accuray (ARAY) Head to Head Contrast

Cogentix Medical (NASDAQ: CGNT) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Valuation & Earnings

This table compares Cogentix Medical and Accuray’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cogentix Medical $51.85 million 3.45 -$22.09 million ($0.41) -7.17
Accuray $383.41 million 1.11 -$29.57 million ($0.35) -14.43

Cogentix Medical has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Cogentix Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cogentix Medical and Accuray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cogentix Medical -36.14% -11.52% -10.04%
Accuray -7.49% -55.18% -6.33%

Analyst Recommendations

This is a summary of current recommendations for Cogentix Medical and Accuray, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cogentix Medical 0 0 3 0 3.00
Accuray 1 2 4 0 2.43

Cogentix Medical presently has a consensus price target of $4.58, indicating a potential upside of 55.90%. Accuray has a consensus price target of $7.17, indicating a potential upside of 41.91%. Given Cogentix Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Cogentix Medical is more favorable than Accuray.

Volatility and Risk

Cogentix Medical has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

13.3% of Cogentix Medical shares are owned by institutional investors. Comparatively, 78.9% of Accuray shares are owned by institutional investors. 62.7% of Cogentix Medical shares are owned by company insiders. Comparatively, 3.9% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cogentix Medical Company Profile

Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply